American Association for Cancer Research
Browse
00085472can140620-sup-127369_1_supp_2509311_n6wnn2.pptx (254.54 kB)

Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy

Download (254.54 kB)
figure
posted on 2023-03-30, 22:50 authored by Laura M. Arthur, Arran K. Turnbull, Victoria L. Webber, Alexey A. Larionov, Lorna Renshaw, Charlene Kay, Jeremy S. Thomas, J. Michael Dixon, Andrew H. Sims

Supplementary Figure 1. ILC-specific and IDC-specific response genes identified from breast cancer cell lines are not significantly changed in response to letrozole in patient tumours. Heatmaps (A), gene set enrichment analysis (B) and specific highlighted genes (C) demonstrate that the reported ILC-specific and IDC-specific genes are not significantly changed between the histological cancer subtypes. Heatmap colours show changes in expression relative to respective patient-matched pre-treatment samples (Red=high, Green=low).

History

ARTICLE ABSTRACT

Invasive lobular carcinoma (ILC) accounts for approximately 10% to 15% of breast carcinomas, and although it responds poorly to neoadjuvant chemotherapy, it appears to respond well to endocrine therapy. Pre- and on-treatment (after 2 weeks and 3 months) biopsies and surgical samples were obtained from 14 postmenopausal women with estrogen receptor–positive (ER+) histologically confirmed ILC who responded to 3 months of neoadjuvant letrozole and were compared with a cohort of 14 responding invasive ductal carcinomas (IDC) matched on clinicopathologic features. RNA was extracted and processed for whole human genome expression microarray. Dynamic clinical response was assessed using periodic three-dimensional ultrasound measurements performed during treatment and defined as a reduction of >70% in tumor volume by 3 months. Pretreatment profiles of ILC and IDC tumors showed distinctive expression of genes associated with E-cadherin signaling, epithelial adhesion, and stromal rearrangement. The changes in gene expression in response to letrozole were highly similar between responding ILC and IDC tumors; genes involved in proliferation were downregulated and those involved with immune function and extracellular matrix remodeling were upregulated. However, molecular differences between the histologic subtypes were maintained upon treatment. This is the first study of molecular changes in ILC in response to endocrine therapy to date. The genes that change on letrozole are highly consistent between ILC and IDC. Differences in gene expression between ILC and IDC at diagnosis are maintained at each time point on treatment. Cancer Res; 74(19); 5371–6. ©2014 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC